(Reuters) – Eli Lilly and Co and Incyte Corp said their rheumatoid arthritis drug baricitinib did not meet the main goal of preventing progression to mechanical ventilation in hospitalized COVID-19 patients under a late-stage study. Patients receiving baricitinib were 2.7% less likely than those receiving standard of care to progress to ventilation, which was not